Metabolic
Ecnoglutide
Also called XW003
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 0.67mg/mL
- Volume per draw
- 1.8mL
- Units to dial
- 180
- Doses per cartridge
- 1
This is 180 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.
Dial range varies by pen; 1–60 units is the common configuration.
Vial label
Copy this into your label printer.
Published research contexts for Ecnoglutide describe 1.2–2.4 mg per administration. Descriptive only, not a recommendation.
Engineered for extended action supporting once-weekly dosing; a precise human half-life is not well characterised in accessible literature.
A cAMP/G-protein-biased GLP-1 receptor agonist studied in phase-2 dose-ranging. The evidence assigned target maintenance amounts reached by stepwise titration, so a single target-range row is shown rather than an invented weekly ramp.
Dosing schedule
How Ecnoglutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Target maintenanceThe phase-2 obesity study assigned target amounts of 1.2, 1.8 or 2.4 mg reached by stepwise titration; the diabetes study used 0.4–1.2 mg. | 1.2–2.4 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Ecnoglutide phase-2 obesity dose-ranging (Sciwind)Once-weekly target amounts of 1.2, 1.8 and 2.4 mg over 26 weeks in adults with overweight or obesity.
- Ecnoglutide type-2 diabetes phase 2 (Nature Communications 2024)Once-weekly 0.4, 0.8 and 1.2 mg over 20 weeks improved glycaemic measures in adults with type-2 diabetes.